Could an organ rejection drug help fight brain cancer?
NCT ID NCT05236036
First seen Jan 15, 2026 · Last updated Apr 24, 2026 · Updated 14 times
Summary
This early-phase trial tests whether adding mycophenolate mofetil (a drug usually used to prevent organ rejection) to standard chemotherapy and radiation can help treat glioblastoma, an aggressive brain cancer. About 60 newly diagnosed patients will receive different doses to find the safest amount and see if the combination makes tumor cells more sensitive to treatment. The goal is to control the disease, not cure it, as ongoing management is still needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwestern Lake Forest Hospital
Lake Forest, Illinois, 60045, United States
-
Northwestern Medicine Warrenville
Warrenville, Illinois, 60555, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
Conditions
Explore the condition pages connected to this study.